Arbutus Biopharma Corporation logo
Arbutus Biopharma Corporation ABUS
$ 4.34 -1.92%

Annual report 2025
added 03-23-2026

report update icon

Arbutus Biopharma Corporation Financial Statements 2011-2026 | ABUS

Annual Financial Statements Arbutus Biopharma Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

847 M 820 M 445 M 421 M 413 M 300 M 159 M 205 M 279 M 135 M 143 M 575 M 199 M 66.3 M 24.3 M

Shares

192 M 186 M 166 M 151 M 106 M 79.5 M 57.1 M 55.3 M 54.1 M 53.1 M 45.5 M 22.4 M 15.3 M 13.7 M 11.3 M

Historical Prices

4.42 4.42 2.68 2.79 3.89 3.55 2.78 3.83 5.05 2.45 4.45 15.2 7.97 4.96 1.5

Net Income

-33.5 M -69.9 M -72.8 M -69.5 M -76.2 M -63.7 M -154 M -57.1 M -84.4 M -384 M -61.1 M -38.8 M -14.1 M 29.9 M -9.73 M

Revenue

14.1 M 6.17 M 18.1 M 39 M 11 M 6.91 M 6.01 M 5.94 M 10.7 M 1.49 M 24.9 M 15 M 15.5 M 14.2 M 16.3 M

Gross Profit

- - - - - -40.6 M -51.6 M -52 M -52 M -59.8 M -26.6 M -23.8 M -5.99 M -3.94 M -3.19 M

Operating Income

-38.2 M -76.3 M -78.1 M -65.5 M -73.5 M -57.8 M -144 M -89.8 M -111 M -492 M -104 M -33.4 M -12.2 M -12.9 M -10.7 M

Interest Expense

- - 459 K 1.73 M 2.86 M 4.01 M 2.11 M 226 K 261 K - - - - - -

EBITDA

-37.8 M -74.9 M -76.7 M -64 M -71.8 M -55.3 M -69.3 M -68 M -68.1 M -99.2 M -53.1 M -32.4 M -11.5 M 34.5 M -9.37 M

Operating Expenses

52.2 M 82.5 M 96.2 M 104 M 84.5 M 16.7 M 19.8 M 18.2 M 18.2 M 40.5 M 27 M 9.21 M 6.16 M -37.6 M 7.14 M

General and Administrative Expenses

15.9 M 22.1 M 22.5 M 17.8 M 17.1 M 14.7 M 17.7 M 16 M 16.1 M 39.4 M 26.4 M 8.68 M 5.55 M 26.9 M 6.18 M

All numbers in USD currency

Quarterly Income Statement Arbutus Biopharma Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

192 M 192 M 191 M 190 M 189 M 188 M 176 M 170 M 168 M 166 M 162 M 157 M 151 M 149 M 148 M 145 M 101 M 96.9 M 93.4 M 89.7 M 79.5 M 69.6 M 67.7 M 64.8 M 56.9 M 56.8 M 55.7 M 55.5 M 55.4 M 55.2 M 55.1 M 55.1 M 54.9 M 54.6 M 54.3 M 54.8 M 53.7 M 52.7 M 51.4 M 54.6 M 50.8 M 54.3 M 30.2 M 22.4 M 22.2 M 22.1 M 19.8 M 19 M 14.5 M 14.4 M 14.3 M 14.3 M - - - 12.1 M - - -

Net Income

-7.74 M 2.52 M -24.5 M - -19.7 M -19.8 M -17.9 M - -20.1 M -17.1 M -16.3 M - -17.6 M -14.2 M -15.8 M - -19.2 M -19.4 M -16.4 M - -18.8 M -14.1 M -13.9 M -24.7 M -82.5 M -23.3 M -23.3 M -18.2 M -24.5 M 3.09 M -17.4 M -35.9 M -11.6 M -18.3 M -18.6 M -219 M -19.6 M -130 M -15.9 M -5.26 M -29 M -14.9 M -12 M -6.17 M -8.6 M -6.08 M -18 M -2.6 M -5.91 M -3.02 M -2.55 M - - - - - - - -

Revenue

529 K 10.7 M 1.76 M - 1.34 M 1.73 M 1.53 M - 4.66 M 4.65 M 6.69 M - 5.95 M 14.2 M 12.6 M - 3.34 M 2.33 M 2.11 M - 1.52 M 1.51 M 1.49 M 1.62 M 3.06 M 653 K 679 K 1.68 M 1.59 M 1.24 M 1.44 M 2.53 M 6.89 M 1.04 M 235 K -195 K 774 K 309 K 603 K 12.7 M 4.06 M 3.44 M 4.68 M 4.35 M 4.36 M 1.81 M 4.43 M 752 K 2.96 M 2.84 M 2.13 M - - - - - - - -

Operating Income

-8.66 M 1.49 M -25.7 M - -21.4 M -21.6 M -19.4 M - -21.6 M -18.4 M -17.4 M - -17.8 M -14.1 M -11 M - -18.4 M -18.6 M -15.7 M - -15.2 M -13.1 M -13.1 M -13.1 M -91 M -20.6 M -19.2 M -16.9 M -32.4 M -22 M -18.4 M -60.2 M -12.9 M -19.5 M -18.3 M -257 M -19 M -195 M -20 M -11.8 M -58.1 M -14.4 M -18 M -10.7 M -6.84 M -9.42 M -5.96 M -2.44 M -3.65 M -3.07 M -2.99 M - - - - - - - -

Interest Expense

- - - - - 34 K 44 K - 46 K 171 K 198 K - 429 K 482 K 506 K - 762 K 763 K 772 K - 1.07 M 1.1 M 1.04 M - 1.1 M 2 K 12 K - - - 104 K - 76 K 68 K 42 K - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - -25.4 M - - - -19 M - - - -17.1 M - -16.7 M -14.1 M -10.6 M - -17.1 M -18.2 M -15.2 M - -13.7 M -12.1 M -12.6 M -13.1 M -90.5 M -20.1 M -18.7 M -16.9 M -31.9 M -21.5 M -17.8 M -60.2 M -12.3 M -19 M -18 M -257 M -18.7 M -195 M -19.8 M -11.8 M -58 M -14.3 M -17.9 M -10.7 M -6.71 M -9.27 M -5.82 M -2.44 M -3.5 M -2.92 M -2.83 M - - - - - - - -

Operating Expenses

9.19 M 9.25 M 27.5 M - 22.8 M 23.3 M 20.9 M - 26.2 M 23 M 24.1 M - 23.8 M 28.4 M 23.6 M - 21.7 M 21 M 17.8 M - 16.7 M 14.7 M 14.6 M - 94.1 M 21.3 M 19.9 M - 34 M 23.3 M 19.8 M - 19.8 M 20.5 M 18.5 M - 19.7 M 196 M 20.6 M - 62.2 M 17.9 M 22.7 M - 11.2 M 11.2 M 10.4 M - 6.61 M 5.92 M 5.13 M - - - - - - - -

General and Administrative Expenses

3.04 M 3.33 M 5.83 M - 4.54 M 7.55 M 5.31 M - 5.84 M 5.98 M 5.55 M - 3.49 M 5.2 M 4.89 M - 4.18 M 4.44 M 3.88 M - 4.06 M 3.57 M 3.55 M - 3.25 M 8.19 M 4.41 M - 2.63 M 3.78 M 3.67 M - 3.66 M 4.6 M 4.33 M - 3.72 M 23.8 M 7.22 M - 7.71 M 7.66 M 2.72 M - 1.76 M 1.79 M 2.05 M - 960 K 849 K 893 K - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Arbutus Biopharma Corporation ABUS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Arbutus Biopharma Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Lipocine Lipocine
LPCN
$ 7.4 1.23 % $ 39 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 217.23 -0.38 % $ 5 B danmarkDanmark
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 19.47 1.25 % $ 910 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 8.28 -1.84 % $ 110 M usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
$ 1.68 2.13 % $ 610 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.74 21.89 % $ 8.48 M israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Exelixis Exelixis
EXEL
$ 41.51 0.23 % $ 11.3 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.36 -3.21 % $ 347 M britainBritain
MediWound Ltd. MediWound Ltd.
MDWD
$ 16.64 -1.42 % $ 453 M israelIsrael
Mesoblast Limited Mesoblast Limited
MESO
$ 14.31 2.07 % $ 9.29 B australiaAustralia
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Genmab A/S Genmab A/S
GMAB
$ 25.73 0.19 % $ 16.5 B danmarkDanmark
Aytu BioScience Aytu BioScience
AYTU
$ 2.61 -0.76 % $ 16.4 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Immatics N.V. Immatics N.V.
IMTX
$ 9.19 -3.36 % $ 578 M germanyGermany
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Ionis Pharmaceuticals Ionis Pharmaceuticals
IONS
$ 69.55 -1.75 % $ 11.1 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Longeveron Longeveron
LGVN
$ 0.87 -8.8 % $ 15.3 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA